Exploration of novel clusters and prognostic value of immune‑related signatures and identify HAMP as hub gene in colorectal cancer
- Authors:
- Hongyuan Wu
- Heling Dong
- Shaofang Ren
- Jianxin Chen
- Yan Zhang
- Meng Dai
- Yinfen Wu
- Xuefang Zhang
-
Affiliations: Department of Radiation Oncology, Affiliated Dongguan People's Hospital of Southern Medical University, Dongguan, Guangdong 523009, P.R. China, School of Sports Education, Jinan University, Guangzhou, Guangdong 510632, P.R. China, State Key Laboratory of Organ Failure Research, Department of Developmental Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Department of General Surgery, Affiliated Dongguan People's Hospital of Southern Medical University, Dongguan, Guangdong 523009, P.R. China, Department of Health Management, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Department of Oncology, Affiliated Dongguan People's Hospital of Southern Medical University, Dongguan, Guangdong 523009, P.R. China - Published online on: July 5, 2023 https://doi.org/10.3892/ol.2023.13946
- Article Number: 360
-
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
 |
 |
 |
|
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. | |
|
Siegel RL, Torre LA, Soerjomataram I, Hayes RB, Bray F, Weber TK and Jemal A: Global patterns and trends in colorectal cancer incidence in young adults. Gut. 68:2179–2185. 2019. | |
|
Kim MJ, Jeong SY, Choi SJ, Ryoo SB, Park JW, Park KJ, Oh JH, Kang SB, Park HC, Heo SC and Park JG: Survival paradox between stage IIB/C (T4N0) and stage IIIA (T1-2N1) colon cancer. Ann Surg Oncol. 22:505–512. 2015. | |
|
Almatroudi A: The incidence rate of colorectal cancer in Saudi Arabia: An observational descriptive epidemiological analysis. Int J Gen Med. 13:977–990. 2020. | |
|
Gan GL, Liu J, Chen WJ, Ye QQ, Xu Y, Wu HT and Li W: The diverse roles of the mucin gene cluster located on chromosome 11p15.5 in colorectal cancer. Front Cell Dev Biol. 8:5142020. | |
|
Sasidharan Nair V, Saleh R, Taha RZ, Toor SM, Murshed K, Ahmed AA, Kurer MA, Abu Nada M, Al Ejeh F and Elkord E: Differential gene expression of tumor-infiltrating CD4+ T cells in advanced versus early stage colorectal cancer and identification of a gene signature of poor prognosis. Oncoimmunology. 9:18251782020. | |
|
Ihnát P, Vávra P and Zonča P: Treatment strategies for colorectal carcinoma with synchronous liver metastases: Which way to go. World J Gastroenterol. 21:7014–7021. 2015. | |
|
Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E and Rodriguez Yoldi MJ: Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. Int J Mol Sci. 18:1972017. | |
|
Ciardiello D, Vitiello PP, Cardone C, Martini G, Troiani T, Martinelli E and Ciardiello F: Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. Cancer Treat Rev. 76:22–32. 2019. | |
|
Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet. 375:1030–1047. 2010. | |
|
de Weger VA, Turksma AW, Voorham QJ, Euler Z, Bril H, van den Eertwegh AJ, Bloemena E, Pinedo HM, Vermorken JB, van Tinteren H, et al: Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer. Clin Cancer Res. 18:882–889. 2012. | |
|
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 372:2509–2520. 2015. | |
|
Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, et al: Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 20:1139–1167. 2022. | |
|
Koncina E, Haan S, Rauh S and Letellier E: Prognostic and predictive molecular biomarkers for colorectal cancer: Updates and challenges. Cancers (Basel). 12:3192020. | |
|
Vacante M, Borzì AM, Basile F and Biondi A: Biomarkers in colorectal cancer: Current clinical utility and future perspectives. World J Clin Cases. 6:869–881. 2018. | |
|
Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 26:1626–1634. 2008. | |
|
Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 27:663–671. 2009. | |
|
Douillard J, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, et al: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 369:1023–1034. 2013. | |
|
Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 359:1757–1765. 2008. | |
|
Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA and Karapetis CS: Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-analysis of randomized, controlled trials. Ann Oncol. 26:13–21. 2015. | |
|
Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, et al: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 29:2011–2019. 2011. | |
|
Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, et al: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet. 377:2103–2114. 2011. | |
|
Le DT, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O'Neil B, Kavan P, Yoshino T, et al: Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 38:11–19. 2020. | |
|
Fu J, Li K, Zhang W, Wan C, Zhang J, Jiang P and Liu XS: Large-scale public data reuse to model immunotherapy response and resistance. Genome Med. 12:212020. | |
|
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, et al: Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 24:1550–1558. 2018. | |
|
Love MI, Huber W and Anders S: Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15:5502014. | |
|
Wang X, Duanmu J, Fu X, Li T and Jiang Q: Analyzing and validating the prognostic value and mechanism of colon cancer immune microenvironment. J Transl Med. 18:3242020. | |
|
Li L, Zhang W, Qiu J, Zhang W, Lu M, Wang J, Jin Y and Xi Q: Stem cell-associated signatures help to predict diagnosis and prognosis in ovarian serous cystadenocarcinoma. Stem Cells Int. 2023:45005612023. | |
|
Hänzelmann S, Castelo R and Guinney J: GSVA: Gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics. 14:72013. | |
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W and Smyth GK: Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43:e472015. | |
|
Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, Hackl H, Krogsdam A, Loncova Z, Posch W, Wilflingseder D, et al: Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 11:342019. | |
|
Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA, et al: Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 4:26122013. | |
|
Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M and Alizadeh AA: Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 12:453–457. 2015. | |
|
Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, Feng T, Zhou L, Tang W, Zhan L, et al: clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2:1001412021. | |
|
Yu G, Wang LG, Han Y and He QY: clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Chin CH, Chen SH, Wu HH, Ho CW, Ko MT and Lin CY: cytoHubba: Identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 8 (Suppl 4):S112014. View Article : Google Scholar : PubMed/NCBI | |
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, et al: An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 173:400–416.e11. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Tang YL, Li DD, Duan JY, Sheng LM and Wang X: Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments. World J Gastroenterol. 29:926–948. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Seliger B: Basis of PD1/PD-L1 Therapies. J Clin Med. 8:21682019. View Article : Google Scholar : PubMed/NCBI | |
|
Pitt JM, Vétizou M, Daillère R, Roberti MP, Yamazaki T, Routy B, Lepage P, Boneca IG, Chamaillard M, Kroemer G and Zitvogel L: Resistance mechanisms to immune-checkpoint blockade in cancer: Tumor-intrinsic and -extrinsic factors. Immunity. 44:1255–1269. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Sun C, Mezzadra R and Schumacher TN: Regulation and function of the PD-L1 checkpoint. Immunity. 48:434–452. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chen DS and Mellman I: Elements of cancer immunity and the cancer-immune set point. Nature. 541:321–330. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, et al: Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-Year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 35:3924–3933. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al: Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 32:1020–1030. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al: Pembrolizumab versus chemotherapy for PD-L1-Positive non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 375:1856–1867. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Danaher P, Warren S, Lu R, Samayoa J, Sullivan A, Pekker I, Wallden B, Marincola FM and Cesano A: Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): Results from The Cancer Genome Atlas (TCGA). J Immunother Cancer. 6:632018. View Article : Google Scholar : PubMed/NCBI | |
|
Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ and Schreiber RD: Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 450:903–907. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Dunn GP, Bruce AT, Ikeda H, Old LJ and Schreiber RD: Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol. 3:991–998. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, et al: Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 353:2654–2666. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang N and Bevan MJ: CD8(+) T cells: Foot soldiers of the immune system. Immunity. 35:161–168. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Alspach E, Lussier DM and Schreiber RD: Interferon γ and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity. Cold Spring Harb Perspect Biol. 11:a0284802019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Zhou N, Zhou L, Wang J, Zhou Y, Zhang T, Fang Y, Deng J, Gao Y, Liang X, et al: IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor. Nat Immunol. 22:358–369. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang J, Endres S and Kobold S: Enhancing tumor T cell infiltration to enable cancer immunotherapy. Immunotherapy. 11:201–213. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Franklin RA, Liao W, Sarkar A, Kim MV, Bivona MR, Liu K, Pamer EG and Li MO: The cellular and molecular origin of tumor-associated macrophages. Science. 344:921–925. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wu D, Liu X, Mu J, Yang J, Wu F and Zhou H: Therapeutic approaches targeting proteins in tumor-associated macrophages and their applications in cancers. Biomolecules. 12:3922022. View Article : Google Scholar : PubMed/NCBI | |
|
Dahlin AM, Henriksson ML, Van Guelpen B, Stenling R, Oberg A, Rutegård J and Palmqvist R: Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Mod Pathol. 24:671–682. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, Levionnois E, Nizard M, Si-Mohamed A, Besnier N, et al: PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 73:128–138. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Vassilakopoulou M, Avgeris M, Velcheti V, Kotoula V, Rampias T, Chatzopoulos K, Perisanidis C, Kontos CK, Giotakis AI, Scorilas A, et al: Evaluation of PD-L1 expression and associated tumor-infiltrating lymphocytes in laryngeal squamous cell carcinoma. Clin Cancer Res. 22:704–713. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Wang S, Song X, Zeng W, Wang S, Chen F and Ding H: The prognostic value of systemic and local inflammation in patients with laryngeal squamous cell carcinoma. Onco Targets Ther. 9:7177–7185. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A and Palmqvist R: High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res. 13:1472–1479. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Jung M, Mertens C, Tomat E and Brüne B: Iron as a central player and promising target in cancer progression. Int J Mol Sci. 20:2732019. View Article : Google Scholar : PubMed/NCBI | |
|
Torti SV and Torti FM: Iron and cancer: More ore to be mined. Nat Rev Cancer. 13:342–355. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Yu L, Ding J and Chen Y: Iron metabolism in cancer. Int J Mol Sci. 20:952018. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang Z, Lim SO, Yan M, Hsu JL, Yao J, Wei Y, Chang SS, Yamaguchi H, Lee HH, Ke B, et al: TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. J Clin Invest. 131:e1394342021. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma P, Hu-Lieskovan S, Wargo JA and Ribas A: Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 168:707–723. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Jacolot S, Le Gac G, Scotet V, Quere I, Mura C and Ferec C: HAMPas a modifier gene that increases the phenotypic expression of the HFEpC282Y homozygous genotype. Blood. 103:2835–2840. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Casu C, Nemeth E and Rivella S: Hepcidin agonists as therapeutic tools. Blood. 131:1790–1794. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Armitage AE, Eddowes LA, Gileadi U, Cole S, Spottiswoode N, Selvakumar TA, Ho LP, Townsend AR and Drakesmith H: Hepcidin regulation by innate immune and infectious stimuli. Blood. 118:4129–4139. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Bessman NJ, Mathieu JRR, Renassia C, Zhou L, Fung TC, Fernandez KC, Austin C, Moeller JB, Zumerle S, Louis S, et al: Dendritic cell-derived hepcidin sequesters iron from the microbiota to promote mucosal healing. Science. 368:186–189. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Vyoral D and Petrák J: Hepcidin: A direct link between iron metabolism and immunity. Int J Biochem Cell Biol. 37:1768–1773. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Mleczko-Sanecka K, Roche F, da Silva AR, Call D, D'Alessio F, Ragab A, Lapinski PE, Ummanni R, Korf U, Oakes C, et al: Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras/RAF and nutrient-dependent mTOR signaling. Blood. 123:1574–1585. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ren F, Yang Y, Wu K, Zhao T, Shi Y, Song M and Li J: The effects of dandelion polysaccharides on iron metabolism by regulating hepcidin via JAK/STAT signaling pathway. Oxid Med Cell Longev. 2021:71847602021. View Article : Google Scholar : PubMed/NCBI | |
|
Saad HKM, Abd Rahman AA, Ab Ghani AS, Taib WRW, Ismail I, Johan MF, Al-Wajeeh AS and Al-Jamal HAN: Activation of STAT and SMAD signaling induces hepcidin re-expression as a therapeutic target for β-Thalassemia patients. Biomedicines. 10:1892022. View Article : Google Scholar : PubMed/NCBI | |
|
Joachim JH and Mehta KJ: Hepcidin in hepatocellular carcinoma. Br J Cancer. 127:185–192. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Kessler SM, Barghash A, Laggai S, Helms V and Kiemer AK: Hepatic hepcidin expression is decreased in cirrhosis and HCC. J Hepatol. 62:977–979. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Maegdefrau U, Arndt S, Kivorski G, Hellerbrand C and Bosserhoff A: Downregulation of hemojuvelin prevents inhibitory effects of bone morphogenetic proteins on iron metabolism in hepatocellular carcinoma. Lab Invest. 91:1615–1623. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Scimeca M and Bonanno E: New highlight in breast cancer development: The key role of hepcidin and iron metabolism. Ann Transl Med. 6 (Suppl 1):S562018. View Article : Google Scholar : PubMed/NCBI | |
|
Tesfay L, Clausen KA, Kim JW, Hegde P, Wang X, Miller LD, Deng Z, Blanchette N, Arvedson T, Miranti CK, et al: Hepcidin regulation in prostate and its disruption in prostate cancer. Cancer Res. 75:2254–2263. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao B, Li R, Cheng G, Li Z, Zhang Z, Li J, Zhang G, Bi C, Hu C, Yang L, et al: Role of hepcidin and iron metabolism in the onset of prostate cancer. Oncol Lett. 15:9953–9958. 2018.PubMed/NCBI | |
|
Chen Q, Wang L, Ma Y, Wu X, Jin L and Yu F: Increased hepcidin expression in non-small cell lung cancer tissue and serum is associated with clinical stage. Thorac Cancer. 5:14–24. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Phipps O, Brookes MJ and Al-Hassi HO: Iron deficiency, immunology, and colorectal cancer. Nutr Rev. 79:88–97. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Colorectal cancer cells ectopically express hepcidin to sequester iron. Cancer Discov. 11:OF22021. View Article : Google Scholar | |
|
Schwartz AJ, Goyert JW, Solanki S, Kerk SA, Chen B, Castillo C, Hsu PP, Do BT, Singhal R, Dame MK, et al: Hepcidin sequesters iron to sustain nucleotide metabolism and mitochondrial function in colorectal cancer epithelial cells. Nat Metab. 3:969–982. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Sornjai W, Nguyen Van Long F, Pion N, Pasquer A, Saurin JC, Marcel V, Diaz JJ, Mertani HC and Smith DR: Iron and hepcidin mediate human colorectal cancer cell growth. Chem Biol Interact. 319:1090212020. View Article : Google Scholar : PubMed/NCBI | |
|
Xiang-Tao P: Expression of hepcidin and neogenin in colorectal cancer. Open Med (Wars). 12:184–188. 2017. View Article : Google Scholar : PubMed/NCBI |
